tert-butyl N-[methyl-[2-methyl-2-(methylamino)propanoyl]amino]carbamate | 870487-34-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-[methyl-[2-methyl-2-(methylamino)propanoyl]amino]carbamate
• CAS: 870487-34-6
• 化学式: C₁₁H₂₃N₃O₃
• 分子量: 245.322
• InChiKey: CRNWKLNRILXZQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[methyl-[2-methyl-2-(methylamino)propanoyl]amino]carbamate 、 PNPC-1918 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 methyl (8S)-8-(chloromethyl)-6-(5-methoxy-1-benzofuran-2-carbonyl)-2-methyl-4-[methyl-[2-methyl-1-[methyl-[(2-methylpropan-2-yl)oxycarbonylamino]amino]-1-oxopropan-2-yl]carbamoyl]oxy-7,8-dihydro-3H-pyrrolo[3,2-e]indole-1-carboxylate
  参考文献：
  名称：

  [EN] SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES
  [FR] BRAS DE LIAISON CHIMIQUES ET CONJUGUES ASSOCIES

  摘要：

  公开号：

  WO2005112919A3
• 作为产物：
  描述：

  在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 tert-butyl N-[methyl-[2-methyl-2-(methylamino)propanoyl]amino]carbamate
  参考文献：
  名称：

  [EN] SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES
  [FR] BRAS DE LIAISON CHIMIQUES ET CONJUGUES ASSOCIES

  摘要：

  公开号：

  WO2005112919A3

文献信息

• CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
  申请人：Sufi Bilal

  公开号：US20100145036A1

  公开（公告）日：2010-06-10

  The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物和药物可切割底物共轭物，它们是有效的细胞毒素。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• CHEMICAL LINKERS AND CONJUGATES THEREOF
  申请人：Boyd Sharon E.

  公开号：US20100092496A1

  公开（公告）日：2010-04-15

  The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

  本公开提供了药物-配体共轭物，其具有强效的细胞毒性，其中药物通过肽基、肼基或二硫键连接到配体上。该公开还涉及含有药物-配体共轭物的组合物，以及使用它们的治疗方法。
• SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES
  申请人：E. R. Squibb & Sons, L.L.C.

  公开号：EP1747021B1

  公开（公告）日：2015-09-09
• Antibody-Drug Conjugates and Methods of Use
  申请人：Boyd Sharon Elaine

  公开号：US20080279868A1

  公开（公告）日：2008-11-13

  The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.
• HUMAN ANTIBODIES THAT BIND CD19 AND USES THEREOF
  申请人：King David John

  公开号：US20100104509A1

  公开（公告）日：2010-04-29

  Human monoclonal antibodies that specifically bind to CD19 with high affinity are disclosed The antibodies are capable of internalizing into CD19-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies are also provided Also provided are methods for detecting CD19, as well as methods for treating cancers, such as B cell malignancies, for example, non-Hodgkin's lymphoma, chronic lymphocytic leukemias, follicular lymphomas, diffuse large cell lymphomas of B lineage, and multiple myelomas using an anti-CD 19 anti-body